RSB Spine signs master distribution agreement with Paradigm BioDevices

RSB Spine, LLC, today announced that it has signed an exclusive master distribution agreement with Paradigm BioDevices, Inc. for the U.S. market. Paradigm BioDevices was instrumental in developing the Stand Alone 360 market for ZERO-Profile(SM) ALIF implants, which is one of the fastest growing segments in the spine market. RSB Spine's growing portfolio of modular fusion products offers surgeons more choices than existing technologies in the zero profile segment of the market. Moreover, RSB Spine will introduce two new products this year, and two additional products in 2010, making the need for effective distribution critical to the ongoing success of the company.

RSB Spine Chief Executive Officer John A. Redmond said: "We are delighted with this partnership and believe that Paradigm BioDevices' proven success and expertise in this market will greatly enhance our efforts to bring unique, surgeon-friendly implants to RSB's customers. Distribution is one of the most difficult aspects of this business, and we are confident that Paradigm BioDevices will provide increased opportunities for access to quality agents and rapid sales growth."

Paradigm BioDevices, Inc., Chief Executive Officer Mike O'Neill said: "RSB's product portfolio is a truly innovative and remarkable platform that offers surgeons the ability to select material and mechanical properties that best meet their patients' individual needs. We are excited to be involved with RSB's unique products and the diverse market opportunity they afford."

Source:

RSB Spine, LLC

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tiam1 inhibition mitigates morphine tolerance and hyperalgesia in mouse model